Suppr超能文献

使用脑肿瘤患者MDASI量表(MDASI-BT)及定性访谈识别原发性脑肿瘤患者的症状复发情况

Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews.

作者信息

Acquaye Alvina A, Payén Samuel S, Vera Elizabeth, Williams Loretta A, Gilbert Mark R, Weathers Shiao-Pei, Armstrong Terri S

机构信息

Neuro-Oncology Branch, National Institutes of Health, 9030 Old Georgetown Rd, Room 231, Bethesda, MD, 20892, USA.

Department of Family Health Houston, The University of Texas Health Science Center of Nursing Research, Houston, TX, USA.

出版信息

J Patient Rep Outcomes. 2019 Aug 23;3(1):58. doi: 10.1186/s41687-019-0143-0.

Abstract

BACKGROUND

Identifying symptoms experienced throughout the disease trajectory is pivotal to understanding management of patient symptoms. Patient interviews to solicit input from those who have experienced these symptoms is one method to capture this perspective to validate symptoms included in patient reported outcomes (PRO) measures.

METHODS

A thematic approach was used to identify themes within qualitative interviews. The MD Anderson Symptom Inventory- Brain Tumor (MDASI-BT) was completed by glioma patients. Descriptive statistics was used for analysis of the MDASI-BT.

RESULTS

Thematic saturation was reached with 23 participants, with a median age of 53 (23-62), on treatment (57%) and diagnosed with a glioblastoma (48%). Patients endorsed 20 out of the 22 MDASI-BT symptoms (symptoms not reported: dry mouth, shortness of breath) during the interviews and with completion of the instrument (seizures and vomiting were not endorsed). Fatigue (55%), seizures (50%), and pain (50%) were common symptoms described by the sample. During treatment, more symptoms were identified with fatigue, hair loss, and nausea more problematic. Aside from itching and swelling (endorsed by 2 patients each), all other symptoms not included in the MDASI-BT instrument were endorsed by only one patient.

CONCLUSIONS

Completion of the MDASI-BT, found patients reported on average 6.8 symptoms with 14% of reported symptoms (mean = 3) rated as moderate to severe. The findings demonstrate how applicable the MDASI-BT is in capturing significant symptoms experienced and how important it is to utilize throughout ones' care to manage symptoms effectively.

摘要

背景

识别疾病全过程中出现的症状对于理解患者症状管理至关重要。通过患者访谈征求有这些症状经历者的意见,是获取这一观点以验证患者报告结局(PRO)测量中所包含症状的一种方法。

方法

采用主题分析法在定性访谈中识别主题。胶质瘤患者完成了MD安德森症状量表-脑肿瘤(MDASI-BT)。使用描述性统计分析MDASI-BT。

结果

23名参与者达到了主题饱和,中位年龄为53岁(23 - 62岁),正在接受治疗(57%),被诊断为胶质母细胞瘤(48%)。患者在访谈期间及完成量表时认可了MDASI-BT的22种症状中的20种(未报告的症状:口干、呼吸急促)(未认可癫痫发作和呕吐)。疲劳(55%)、癫痫发作(50%)和疼痛(50%)是样本中描述的常见症状。在治疗期间,发现更多症状中疲劳、脱发和恶心问题更大。除瘙痒和肿胀(各有2名患者认可)外,MDASI-BT量表未包含的所有其他症状仅被1名患者认可。

结论

完成MDASI-BT后发现,患者平均报告6.8种症状,报告症状中有14%(平均 = 3)被评为中度至重度。研究结果表明MDASI-BT在捕捉所经历的重要症状方面的适用性,以及在整个护理过程中有效管理症状时使用它的重要性。

相似文献

1
Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews.
J Patient Rep Outcomes. 2019 Aug 23;3(1):58. doi: 10.1186/s41687-019-0143-0.
2
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).
J Neurooncol. 2006 Oct;80(1):27-35. doi: 10.1007/s11060-006-9135-z. Epub 2006 Apr 6.
3
Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D.
Neurooncol Pract. 2018 Mar;5(1):56-63. doi: 10.1093/nop/npx010. Epub 2017 Jul 4.
4
Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module.
Jpn J Clin Oncol. 2020 Jul 9;50(7):787-793. doi: 10.1093/jjco/hyaa036.
6
Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module.
Neurooncol Pract. 2020 Oct 19;8(2):137-147. doi: 10.1093/nop/npaa068. eCollection 2021 Apr.
7
Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module.
J Neurosurg Spine. 2010 Apr;12(4):421-30. doi: 10.3171/2009.10.SPINE0943.
8
Clinical utility of the MDASI-BT in patients with brain metastases.
J Pain Symptom Manage. 2009 Mar;37(3):331-40. doi: 10.1016/j.jpainsymman.2008.02.011. Epub 2008 Aug 3.
9
Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer.
J Pain Symptom Manage. 2013 Dec;46(6):837-45. doi: 10.1016/j.jpainsymman.2013.02.007. Epub 2013 Apr 22.

引用本文的文献

1
Clinical Outcome Assessment Tools for Evaluating the Management of Gliomas.
Cancers (Basel). 2025 May 14;17(10):1659. doi: 10.3390/cancers17101659.
3
Symptom management in adult brain tumours: A literature review.
Nurs Open. 2023 Aug;10(8):4892-4906. doi: 10.1002/nop2.1795. Epub 2023 Apr 30.
4
Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors.
Cancer. 2021 Dec 1;127(23):4470-4480. doi: 10.1002/cncr.33849. Epub 2021 Aug 6.

本文引用的文献

4
Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
Neuro Oncol. 2016 Mar;18 Suppl 2(Suppl 2):ii13-ii20. doi: 10.1093/neuonc/nov291.
6
The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms.
Neuro Oncol. 2016 Feb;18(2):252-60. doi: 10.1093/neuonc/nov166. Epub 2015 Aug 19.
7
Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.
Curr Treat Options Oncol. 2014 Dec;15(4):519-28. doi: 10.1007/s11864-014-0302-8.
8
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验